Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Downgrades
  • Earnings
  • General
  • Guidance
  • Health Care
  • Movers
  • News
  • Trading Ideas

Analyst Downgrades Dental Player Envista As Outlook Hinges on Improved Commercial Execution, Strategic Initiative Effectiveness

By Vandana Singh
February 8, 1:57 PM
Envista Holdings Q3 2024 sales beat estimates at $645.6 million. William Blair downgrades to Market Perform with concerns on execution.

NVST

Read More
2 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • News

Baxter Says 2023 Performance Reflects Strategic Initiatives With New Operating Model Without BioPharma Solutions Unit

By Vandana Singh
February 8, 1:51 PM
Baxter's Q4 2023 results: $3.89 billion revenue, surpassing consensus, 4% Y/Y growth. Strong sales in Medical Products, Therapies, Kidney Care, and Pharmaceuticals segments.

BAX

Read More
1 minute read
  • General
  • Health Care
  • Management
  • News

What’s Going On With Health Insurance Firm UnitedHealth Stock Today?

By Vandana Singh
February 8, 12:44 PM
Explore UnitedHealth Group Inc stock insights! Discover recent market trends, CEO perspectives, and financial highlights.

CVS

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

What’s Going On Eli Lilly Stock Thursday?

By Vandana Singh
February 8, 11:36 AM
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews.

LLY

Read More
3 minute read
  • Analyst Color
  • Biotech
  • Econ #s
  • Health Care
  • Top Stories

The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry

By Piero Cingari
February 8, 10:58 AM
Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company.

CMG

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News

AstraZeneca Stock Tumbles After Q4 Performance – Here’s Why

By Vandana Singh
February 8, 8:51 AM
AstraZeneca Q4 2023: $12.02 billion sales, 7% Y/Y growth, fueled by global demand for cancer drugs. Excluding COVID-19 meds, revenue rises 16%. CEO Soriot projects low double-digit growth in 2024.

AZN

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Price Target
  • Trading Ideas

Analysts Boost Eli Lilly’s Forecast With High Hopes On Mounjaro, Zepbound Performance

By Vandana Singh
February 7, 3:49 PM
Eli Lilly's SYNERGY-NASH Phase 2 study results and positive market outlook drive BMO's raised price target to $865. Morgan Stanley remains bullish on Mounjaro/Zepbound launch. BofA Securities cites growth potential.

LLY

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Price Target
  • Reiteration
  • Trading Ideas

Investors’ Focus Around Amgen’s Obesity Drug Data Shadows Better Than Expected Q4 Earnings

By Vandana Singh
February 7, 3:36 PM
Amgen's Q4 2023: 15% net profit growth, $8.2 billion total revenues beat expectations. Prolia leads with 12% sales jump. Analysts' reactions and price targets.

AMGN

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

Why Is Gene Therapy-Focused REGENXBIO Stock Trading Higher Today?

By Vandana Singh
February 7, 1:59 PM
REGENXBIO's progress in Duchenne muscular dystrophy and MPS II treatment trials. Interim results for RGX-202 in Phase 1/2 trial and significant milestones achieved in Phase 1/2/3 trial with RGX-121.

RGNX

Read More
2 minute read
  • FDA
  • General
  • Health Care
  • News

Catalent’s Bloomington Plant Making Novo Nordisk’s Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns

By Vandana Singh
February 7, 1:02 PM
Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic.

CTLT

Posts pagination

Previous 1 … 61 62 63 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service